Essential Biotechnology LLC is striking at the heart of cancer with new antibody therapy that hits not only a new target, but the right target. With their discovery of the existence of Cisplatin Related Protein-9 (CRR9) specifically on the surface of tumor cells, Essential Biotechnology LLC has developed monoclonal antibody inhibitors of CRR9 (EB-102) and shown striking pre-clinical anti-tumorigenic effects and resensitization to chemotherapy. The emerging understanding of cancer cells’ requirement for CRR9 for survival of cellular stress has revealed a vulnerability and a rare opportunity for more effective targeted therapy.
We have a lean and focused clinical development plan for EB-102, driven by over 45 years of experience in industry and clinical development. Recurrent ovarian cancer is our initial target for clinical trials given our ability to resensitize ovarian tumor cells to platinum-based chemotherapy. This technology promises to be highly effective in a variety of cancers.